Thank and today. and call for the all you, joining thank webcast Jeremy the you
and first momentum started one have of promise only a XXXX challenge with could anticipated. tremendous end no quarter global to The with great
needs poise and rallied with team adapted our the unwavering well-being with great and to commitment customers' of Our our along safety and staff.
we virus system this those battling serving who Our lives. in this the than health care lines of saving that more of team global understands part observers are are greater pandemic but a a and front on
Asia-Pacific, current care existing carotid planning more to restart look CGuard EPS as momentum in and technology position I'm our procedures South and growth We disrupt markets EPS expansion while of to to MicroNet enthusiastic forward course, ever America, U.S. of CGuard standard in of potential its very share with the than regaining continuing build of markets proud on in disease. our all elective the in about artery and novel the fundamentally
for and capabilities. flow the call. year I for use that MicroNet growing reiterate the research new this introduced protection my March the reverse recapping our with of morning the our for my proximal of see future pipeline indications into technology and progress vision since along leveraging our spend numerous in and I opportunities time also were will CGuard using our first devices beginning
I'd to like a to on about our and moment impact the a address COVID-XX take more bit its ongoing business. pandemic
seamless environment and procedures of priority say me top all are that safety where health our incorporated necessary and let First the and of and the of employees our remotely. many an remains transition we've to ensure a associates technologies foremost, to our working
continues unprecedented collective while vascular solutions. the pandemic work So, goal world around our caused our the has of delivering team to disruptions clearly next-generation business toward
to around the a transitioning epidemic immune categories: experienced and compromised and systems in that and conditions. those resources many underlying capacity was due quarter, especially world During spreading and localized the global first Healthcare strain the systems older from unprecedented symptoms the high-risk experienced pandemic. patients severity became of already virus by it clear other a availability health to on
stenosis to hit carotid and Italy which at terms which we least decline timing, of of been experience Spain treatment most since is have territories include began the volume result, procedure a As particularly key our in hard virus. elective in a in by
to support using that intact. as organization this as our both ability to firmly supply product ensure remains are We well time our
partners the more our needs fulfill and immediately a distributor system reemerges. patients physicians of to is as health goal care Our normalized their
behind the worst today may that speak encouraging are there worth that indications beginning is procedures European which systems as I healthcare us. certain reopen to noting are be to It is elective that
in have as we're combined that emerges the respond maintain staff enable us and so been with majority extend cash to temporary cash quickly Board that leadership, and of action will implemented our of when up. compensation. runway levels continue from to company additional to strong Directors cost-cutting procedural reduction pick prepared This volumes that ensure the as measures have employees, to senior To this our crisis possible, a agreed our our
continue look for in to our of facets organization. will We efficiencies all
for generated revenues $XXX,XXX. the representing Now, XXXX of during over increase first $X.XXX We million some quarter revenue good news. of an quarter XXX% of total first
product of first quarters. in the at Recall sterilization sales issues us the quarter sterilize resulted being estimated or that partner of during deferred our quarter. unable ultimately were backlog we the Based that that impact experienced subsequent into be approximately on equipment ship the $XXX,XXX of for time most to our XXXX to
sterilization revenue such $XXX,XXX with markets CGuard particular, as Total again uptake generated ago. that even the first of Spain. and Italy, quarter with $XXX,XXX, over year in XXX% strong continued by Our revenue driven in was an the in Poland XXXX we key was growth increase issue measured previously of a CGuard,
deceleration the the this more of financials exclude that elaborate the of subsequent but worth alluded particularly a first it to, that the from year year estimated course, in this XXXX the ago increased with have was We're to will period. would reflective the I we of than procedural period impact revenue sales in the we to more quarter. noting volumes backlog, even result, started sterilization-related prior Craig end in XX% CGuard if moment. see Of and the growth just as sterilization issue pleased toward is normalize revenue partially quarter delays still on more
open-cell of be story, for may is lead Taking what who the from periprocedural stroke. with caused by most advanced the to the those postprocedural the designed can struts, advanced a stent an through embolic step the be plaque prolapse protection CGuard, traditional believe and the platform solution, events, system, embolic protection to which to stent new back we to deliver flexibility
as associated in truly alternative double establish outcomes of MicroNet such with carotid artery to stroke prevention. potential clinical of standard created procedure. new for artery surgical conventional against management a stent CGuard procedures endarterectomy, protection well and dimension major disease, of care unique a patients prolapse as as a mitigates and invasive CGuard’s the layered embolization types, new carotid disease shown has treatment or has technology and for the carotid superior next-generation stents,
In an January, around we were and superiority together XX-year-old selected due high-risk CGuard. live showcase the disease. ease to I the for third XX case a also interventionalists patient we and very of at case CGuard with invited year the surgeons leading patient was the attend CGuard at the safety in format features The able conference of conference, procedure case LINC to brings lasted an clinical angiographic that The a for use were an and challenging, shutdown, symptomatic COVID-XX from that to highlighted had consecutive attend CGuard. last which at LINC result. had involving carotid The world. the vascular artery and of minutes excellent the demonstrated outcome approximately opportunity clinical presentations presented number exceptional of to LINC
The IRONGUARD of their trial, or routine X EPS major clinical with multi-specialist practice is carotid and XX-day in no XXX suggested with patients which the associated artery enrolled use complications. disease multi-center, CGuard real-world analysis, large neurological periprocedural
in conferences indicating Additionally, far, growth. LINC, medical EPS device-related the of out University five or Participation long-term Hospital, the years, and safety no thus showed such benefit. Krakow by trial drive PARADIGM-Extend help as high-visibility events sustained Professor procedural-related study awareness longest-running to CGuard Musialek conducted and
vascular of be surgical. potential market majority coronary disease, market, and look artery it abdominal to vast not minimally from of procedures. CGuard the aneurysms, endovascular helpful to When you aortic cerebral addressable around within these endovascular, context the To of at disease, peripheral conditions the thoracic, are understand convergence put may for surgery those treatments invasive some artery now aneurysms treatments our
remains carotid disease the many endarterectomy. performed converting from of potential creating Figures for tremendous XX% treatments are CAD surgery, that CGuard. as via artery frontier Carotid growth of last still suggest as
traditional the I is there unprotected our the towards just believe clinical solution, with given change advantages conditions So other open-strut MicroNet-protected stents. carotid sea combined a stenting we with listed, over
to robust. as vascular plan. market is This community flow solutions, our to very into reverse such the continue we believe We strategic priority why remains be a adjunctive and build growth the surgeon
poised we the segment We believe for have coming a a market in expansion years. in rapid platform what technology that superior is is
immediate Our the outcomes awareness CGuard. superior reported of focus patient with creating remains being
commercial our pandemic. and growing execution Spain the continue in key our Italy, markets, where to Germany, prioritize share prior rapidly been including We has Poland, market to European
and COEs. or commercial cultivation our in CGuard includes strategy program, Centers of outreach efforts parallel education with physician Our Excellence growing of our
has South program been expand to and established COE across America. we Our and are working India Europe program into the
key with will program and the a the to goal awareness As population vascular as program, of programs will who of make the patient in this online with to utilization, initiative to remain the an Excellence we're in our Centers scheduling adjustments the result growing toward of along more available by wish COEs, which a necessary It hands-on ongoing our COVID-XX interest happen to and participate making restrictions, and interactive option. particularly momentum this is of maintain possible long way our broadest CGuard go surgeon community. driving physicians
registrations to with product have elongated associated partners approvals work We been in growth. time these we develop key continuing continue and the been other and internal and Asia to achieve have distribution our And Latin America. channel Europe, these in contracts additional countries, by for lines with while milestones efforts COVID-XX,
the world is, growth. Brazil fifth-largest our the important in artery carotid represents disease therefore, to market and
in approval. and are Brazil great have general We the for growth an for We with America registration provided authorities for health us. all have information Latin required imminent waiting believe potential and optimistically
special French remains delaying authorities, particularly with regarding by our The a unfortunately strategy, market French the it's but been hard our growth CGuard. discussions in hit pillar European pandemic, health for reimbursement of
work on We for advancing increased reimbursement. continue approval this our focus to
Both priority potential we continue progress and the In China in future. both China, positive current hope addressable and market near to have for we the business. news front and than with as our double that our on Japan to both -- markets another are discussions strategic more these such and represent partners
strategic completion of bench and had have believe would the allow eventual an concurred the us States. a IDE requirements support data the information our An to We the market launch now study indicated successfully testing EPS device. in with is support completed that previously satisfy required CGuard initiate We the of to FDA's to to approval design all commercial clinical that our United of overriding requests. process we approval trial objective the FDA
development and the all-important now So in regulatory be we favorable are U.S. gaining approval in agency's the would step commencing market. response, an eagerly important which awaiting if
we be terms well expand at potential peripheral other carotid to broadening as as In as development business effectively conditions. stroke vein artery explore demonstrated other and iliac, presented such CAD CGuard grafts within treatment. portfolio EPS as investigator-initiated disease, outside CGuard of research of our artery as indications of to opportunities continue artery disease, disease, treatment in well LINC of saphenous used subclavian to SVGs, the indications or future for The
results with expanded design noted of closely have COVID-XX CGuard made We've used to important in EPS positioning with these work these We and and applications. to time who these on observations. reduction work this our have of clinicians study procedural KOLs
alternative incorporating leading forward strategic principles to protection Additionally to vascular a as surgeons periprocedural our of viable and pathway. as to look growth mentioned working previously, in exploring the to of the We includes use that this our femoral to central our on this flow franchise CAD continued EPS is with of device and and focus initiative strategy a reverse Part adjunctive their portfolio, on CGuard efforts advancing as access. vascular surgeons alternative endarterectomy. an within adding our
four intellectual it for property In prolific and our issued bolstering a in globally. patents terms us the issued of had year was XXXX franchise. U.S. We in XX further
More second property vascular build pipeline half unique the to products. believe In particular to on bolster the and simple treat of that solutions on XXXX also were is will issued of XXXX, intellectual one what in to most and protection in broad we continue in elegantly but protect expand and coverage potential our patents importantly, disease. CGuard, we
share of to commercial CGuard CAD uniquely care through addressing we market. deserve further of CGuard as MicroNet refer our advantage in unique working EPS to and advanced clinical EPS and that the CAS. of of solution has messaging as standard team a level refine been technology MicroNet-protected process pleased I'm demonstrating a definition the differentiation superiority a and to our The segmented platform,
MicroNet-protected CAS XX,XXX over that devices category performance. believe a sold an With unmatched meaningful definition will and performance product be and clinical our as positioning to record, we
other our and XXXX. new in awareness forward and and branding look will to and comprehensive We marketing campaign in this advancements
turn With Craig call that, I'll Craig. review to over to the financials. our
